Table 1.

Characteristics of our population at the start of the start of the treatment.

Total patients	5300
Treatment courses	5932
	Mean ± SD
Age, years	53.74 ± 14.85
BMI, kg/m2	27.31 ± 5.29
PASI at Baseline	14.42 ± 7.08
	N (%)
Male	3898 (65.71)
PsA	1330 (22.42)
CMD	2919 (49.21)
Difficult-to-treat Areas	2716 (45.79)
Bio-Naïve	2744 (46.26)
Current Biological Drug
Ustekinumab	347 (5.85)
Brodalumab	676 (11.40)
Secukinumab	1412 (23.80)
Ixekizumab	1183 (19.94)
Tildrakizumab	488 (8.23)
Risankizumab	977 (16.47)
Guselkumab	849 (14.31)

BMI, Body Mass Index; PsA, Psoriatic arthritis; PASI, Psoriasis Area and Severity Index; CMD, cardiometabolic diseases; SD, Standard Deviation.